FindTrial
Sign In

Oral or intravenous Tranexamic Acid for visual improvement during surgery in patients undergoing repair of shoulder tendon tears

Oral or intravenous tranexamic acid to improve visual clarity in the intraoperative period of patients undergoing arthroscopic repair of rotator cuff tears in the shoulder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-289z7vn
Enrollment
Unknown
Registered
2022-02-11
Start date
2020-08-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder rotator cuff tendon trauma

Interventions

Intravenous tranexamic acid group (G1): 20 patients will receive tranexamic acid administered at a dose of 15 mg/kg intravenously 10 minutes before the skin incision. In keeping with the double-blind
D014148

Sponsors

Universidade Federal do Maranhão
Lead Sponsor
Universidade Federal do Maranhão
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Both genders; 18 years or older; diagnosis of rotator cuff tear and failure of conservative treatment for more than 3 months.

Exclusion criteria

Exclusion criteria: Modified Coagulation test; kidney disorder; liver disorder; uncontrolled hypertension, considering systolic pressure greater than 180 mmHg; allergic to anesthetic agents or tranexamic acid.

Design outcomes

Primary

MeasureTime frame
Results are expected to demonstrate improvement in intraoperative visual clarity of arthroscopic repairs of shoulder rotator cuff tears with the use of Tranexamic Acid.—

Secondary

MeasureTime frame
It is expected a reduction in postoperative pain, shortening of the hospitalization time and a reduction in the cost of performing the arthroscopic procedure.—

Countries

Brazil

Contacts

Public ContactPlinio Leal

Hospital São Domingos

pliniocunhaleal@hotmail.com55 98 3216-8100

Outcome results

None listed

Source: REBEC (via WHO ICTRP)